Semaglutide: what the research shows.

What is semaglutide?

Semaglutide is a 31-amino-acid peptide modeled on human GLP-1, with chemical modifications that make it resist breakdown and last about a week in the body. Developed by Novo Nordisk, it is approved in the US as Ozempic (type 2 diabetes, weekly injection), Wegovy (obesity, weekly injection), and Rybelsus (type 2 diabetes, daily oral tablet — the first peptide in its class that survives oral dosing).

Like tirzepatide, it is a regulated prescription medicine; "research-grade" semaglutide sold online sits entirely outside that system.

How it works

Semaglutide activates the GLP-1 receptor, mimicking the gut hormone GLP-1:

• increases glucose-dependent insulin release (only when glucose is high)
• suppresses glucagon after meals
• slows stomach emptying
• acts on brain appetite centers, reducing hunger and food intake

Unlike tirzepatide it acts on one receptor only — which makes it the cleanest example for understanding what the GLP-1 pathway alone can do.

What researchers are studying

• Obesity and weight management (STEP program)
• Glycemic control in type 2 diabetes (SUSTAIN program)
• Cardiovascular outcomes (SELECT trial, 2023)
• Oral peptide delivery methods
• Comparisons with dual and triple agonists

What the research shows

• STEP 1 (NEJM 2021; ~1,900 adults with obesity): mean weight reduction of 14.9% over 68 weeks at the 2.4 mg dose, versus 2.4% on placebo.
• SELECT (2023): reduced major cardiovascular events in people with obesity and established cardiovascular disease.
• Common side effects are gastrointestinal — nausea, vomiting, diarrhea — most frequent during dose escalation.

Research limitations

• Effects depend on continued treatment; trial data show weight regain after discontinuation in most participants.
• Muscle mass loss alongside fat loss is documented and still being characterized.
• Long-term safety beyond 2–4 years relies on post-approval surveillance.
• All published dosing is under medical supervision; nothing is known about unregulated use contexts.

Common terminology

• GLP-1 receptor agonist — a molecule mimicking the GLP-1 hormone at its receptor.
• Half-life extension — chemical modifications that slow breakdown (here, fatty-acid binding to albumin).
• Glycemic control — management of blood glucose levels.

Researchers evaluating semaglutide material should understand peptide purity and identity testing — GLP-1 peptides have been a category where counterfeits have appeared. For broader sourcing guidance, see our vendor red flags article.